Stocktoria
PROVECTUS BIOPHARMACEUTICALS, INC. PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. statistics & valuation
Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -1575.3% | -734.4% | -520.2% | -346.6% | — | — | — | — | — | — |
| Net margin | -1615.8% | -766.9% | -556.2% | -359.4% | — | — | — | — | — | — |
| Return on assets | -778.6% | -470.3% | -214.1% | -174.5% | -157.7% | -1133.3% | -468.7% | -410.1% | -393.4% | -435.3% |
| Return on equity | 86.2% | 79.3% | 40.8% | 57.1% | 132.3% | 22.1% | 28.8% | 46.8% | 134.9% | -704.1% |
| Current ratio | 0.08 | 0.14 | 0.15 | 0.23 | 0.45 | 0.01 | 0.33 | 0.25 | 0.27 | 0.85 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.